Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.

M Vincent, A P Kudelka, J J Kavanagh, J Wolf, C F Verschraegen, C Levenback, M Bevers, E Loyer

Journal: Annals of the New York Academy of Sciences 2001;922():349-51

PMID: 11193920

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Address: Secion of Gynecologic and Medical Therapeutics, Department of Gynecology Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. [email protected]

DOI: 10.1111/j.1749-6632.2000.tb07062.x

Link outs

Free resources

Medical:

https://medlineplus.gov/ovariancancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Antineoplastic Agents, Phytogenic, Bridged-Ring Compounds, Camptothecin, Drug Administration Schedule, Drug Resistance, Multiple, Fallopian Tube Neoplasms, Female, Humans, Infusions, Intravenous, Ovarian Neoplasms, Peritoneal Neoplasms, Platinum Compounds, Taxoids, Topotecan